Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA ( (DE:VP4) ) has provided an announcement.
Vistin Pharma ASA has announced that it will release its first quarter results on April 25, 2025, and will host a conference call for shareholders and interested parties on the same day. The call, which will be conducted in English, will include a management discussion followed by a Q&A session, providing stakeholders with insights into the company’s performance and strategic direction.
More about Vistin Pharma ASA
Vistin Pharma is a Norwegian pharmaceutical company specializing in the production of Metformin Hydrochloride, an active pharmaceutical ingredient (API). The company also offers Metformin in the form of Direct Compressible lubricated granules. As a dedicated European producer of Metformin, Vistin Pharma is a key supplier to leading pharmaceutical companies. Headquartered in Oslo, Norway, the company operates a specialized manufacturing facility in Kragerø and employs highly qualified personnel.
YTD Price Performance: -2.25%
Technical Sentiment Signal: Hold
Current Market Cap: €85.92M
For an in-depth examination of VP4 stock, go to TipRanks’ Stock Analysis page.